North America’s medical devices industry saw a flat growth in deal activity during April 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 74 medical devices industry deals worth $963.04m were announced for the region in April 2019, against the 12-month average of 74 deals.
Of all the deal types, venture financing saw most activity in April 2019 with 56 transactions, representing a 75.7% share for the region.
In second place was M&A with 12 deals, followed by private equity deals with six transactions, respectively capturing a 16.2% and 8.1% share of the overall deal activity for the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, venture financing was the leading category in North America’s medical devices industry with $519.55m, while M&A and private equity deals totalled $290.3m and $153.19m, respectively.
North America medical devices industry deals in April 2019: Top deals
The top five medical devices deals accounted for 53.2% of the overall value during April 2019.
The combined value of the top five medical devices deals stood at $512.5m, against the overall value of $963.04m recorded for the month. The top announced medical devices deal tracked by GlobalData in April 2019 was Medline Industries’ $167.5m asset transaction with AngioDynamics.
In second place was the $120m acquisition of GenePOC by Meridian Bioscience and in third place was Oberland Capital Management’s $100m private equity deal with NorthStar Medical Radioisotopes.
The $65m venture financing of Pulmonx by Ally Bridge Group, ArrowMark Partners, Driehaus Capital Management and RTW Investments and General Atlantic and General Catalyst Partners’ venture financing of PathAI for $60m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
